Douglas R. Adkins
Washington University in St. Louis(US)University of Missouri–St. Louis(US)Jewish Hospital(US)Symphony Technology (United States)(US)Washington University Medical Center(US)Alvin J. Siteman Cancer Center(US)University of Missouri–Kansas City(US)
Publications by Year
Research Areas
Head and Neck Cancer Studies, Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immune Cell Function and Interaction
Most-Cited Works
- → Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study(2018)1,654 cited
- → Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology(2020)1,337 cited
- → Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial(2013)739 cited
- → NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018(2018)624 cited
- → NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022(2022)511 cited
- → Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)